Literature DB >> 22361659

A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development.

Pradeep B Lukka1, James W Paxton, Graham J Atwell, Philip Kestell, Bruce C Baguley.   

Abstract

Drug lipophilicity is a vital physicochemical parameter that influences drug absorption, distribution, metabolism, excretion and toxicology. A comparative study of a homologous series based on a pharmaceutically active drug represents a powerful approach to the study of the effects of drug lipophilicity. We have developed a rapid and sensitive LC-MS/MS method suitable for such a homologous series and applied it to a series of DNA binding benzonaphthyridine-based antitumour drugs of differing lipophilicity. The method used a gradient elution with a run time of 7 min for simultaneous quantitation of five analogues in a pooled sample. Method validation was carried out in plasma (human and mouse) and mouse tissues (brain, heart, kidney, liver and lung). It had a limit of quantitation of 0.001 μmol/L and was linear (0.001-0.3 μmol/L) in all matrices with acceptable intra- and inter-assay precision and accuracy. This method allowed the pharmacokinetic parameters of these compounds in mice to be related to their lipophilicity as determined by their partition coefficient (LogD). Both the plasma CL (r=0.95; P=2×10⁻⁷) and V(ss) (r=0.95; P=2×10⁻⁷) exhibited a significant positive correlation with LogD values after intravenous bolus administration to mice. Consequently the plasma mean residence time for each of these five analogues decreased with increasing lipophilicity. There was also a significant positive correlation (r=0.91; P=2×10⁻⁷) between LogD values and the brain to plasma AUC ratio indicating the importance of lipophilicity in the distribution of these compounds into the brain tissue. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22361659     DOI: 10.1016/j.jpba.2012.01.022

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial.

Authors:  Michel Paquette; Éric Lavallée; Serge Phoenix; René Ouellet; Helena Senta; Johan E van Lier; Brigitte Guérin; Roger Lecomte; Éric E Turcotte
Journal:  J Nucl Med       Date:  2017-08-10       Impact factor: 10.057

2.  A mass spectrometric method for in-depth profiling of phosphoinositide regioisomers and their disease-associated regulation.

Authors:  Shin Morioka; Hiroki Nakanishi; Toshiyoshi Yamamoto; Junya Hasegawa; Emi Tokuda; Tomoya Hikita; Tomoko Sakihara; Yuuki Kugii; Chitose Oneyama; Masakazu Yamazaki; Akira Suzuki; Junko Sasaki; Takehiko Sasaki
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.